WO1991010448A1 - Antigene de surface cellulaire associe a l'apoptose cellulaire - Google Patents

Antigene de surface cellulaire associe a l'apoptose cellulaire Download PDF

Info

Publication number
WO1991010448A1
WO1991010448A1 PCT/EP1990/000111 EP9000111W WO9110448A1 WO 1991010448 A1 WO1991010448 A1 WO 1991010448A1 EP 9000111 W EP9000111 W EP 9000111W WO 9110448 A1 WO9110448 A1 WO 9110448A1
Authority
WO
WIPO (PCT)
Prior art keywords
apo
cells
apoptosis
antibody
cell
Prior art date
Application number
PCT/EP1990/000111
Other languages
English (en)
Inventor
Peter H. Krammer
Original Assignee
German Cancer Research Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by German Cancer Research Center filed Critical German Cancer Research Center
Priority to JP2502015A priority Critical patent/JP2963535B2/ja
Priority to CA002071205A priority patent/CA2071205C/fr
Priority to PCT/EP1990/000111 priority patent/WO1991010448A1/fr
Priority to EP90901787A priority patent/EP0511202B1/fr
Priority to DE69009497T priority patent/DE69009497T2/de
Priority to AT90901787T priority patent/ATE106248T1/de
Priority claimed from CA002071205A external-priority patent/CA2071205C/fr
Publication of WO1991010448A1 publication Critical patent/WO1991010448A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • Cell surface molecules play crucial roles in lymphocyte growth control. Such molecules may function as receptors for growth-stimulating cytokines or be associated with receptors and transmit signals essential for growth regulation. Receptor blockade or removal of the
  • stimulating cytokines can lead to decreased lymphocyte growth. For example, withdrawal of interleukins slows human lymphocyte growth and finally leads to a
  • Apoptosis is the most common form of eukaryotic cell death and occurs in embryogenesis, metamorphosis, tissue atrophy, and tumor regression.
  • TNF tumor necrosis factor
  • LT lymphotoxin
  • DNA ladder fragmentation into multimers of about 180 base pairs
  • apoptosis of immature thymocytes in vitro C. A. Smith et al., Nature 337, 181 (1989). It has been suggested that CD3-triggered apoptosis might be responsible for negative selection of T cells in the thymus. The selective induction of apoptosis in cells, such as diseased cells, could prove a useful therapeutic tool.
  • This invention pertains to a cellular surface antigen, designated APO-1, that is associated with cellular apoptosis and to binding agents, such as antibodies, fragments or analogues thereof, which specifically bind to APO-1 and induce inhibition of cell growth or cellular apoptosis.
  • APO-1 has a molecular weight of about 52 kD and is expressed by activated and malignant lymphoid cells. The binding of antibody to APO-1 induces apoptosis and thus, antibody or analogous binding agents can be used to induce growth inhibition or apoptosis in cells, such as lymphoid tumor cells, which carry the APO-1 antigen.
  • Figure 1 shows an autoradiogram of a SDS polyacrylamide electrophoretic gel for determination of the molecular weight of APO-1.
  • Figure 2 shows the induction of growth inhibition and apoptosis by anti-APO-1.
  • Figure 3 illustrates anti-APO-1-induced regression of a lymphoma in mice.
  • Figure 4 shows the localization of anti-APO-1 antibody in xenografts of a lymphoid tumor.
  • the antigen APO-1 is a cellular membrane antigen having a molecular weight of appoximately 52kD as determined by SDS-polyacrylamide gel electrophoresis.
  • APO-1 is
  • lymphoid tumor cells including B cell, T cell and HTLV- 1-associated malignant cells such as adult T cell
  • APO-1 can be isolated from the cellular membrane of cells (such as lymphoid cells) which express the antigen by conventional techniques. Further, the gene encoding APO-1 can be cloned and expressed to provide the isolated antigen or portions of it. Isolated APO-1 can be used as immunogen to raise anti-APO-1 antibody (polyclonal or monoclonal) or to screen for production of anti-APO-1 antibody by hybridomas, of chimeric anti-APO-1 antibody by transfected myelomas or of single chain anti-APO-1 antibody by transformed bacterial cells.
  • Antibodies which bind to APO-1 are useful for inducing inhibition of cell growth or apoptosis in cells that express APO-1.
  • monoclonal anti-APO-1 antibodies are preferred.
  • antibodies are produced by continuous (immortalized), stable, antibody-producing cell lines.
  • the preferred antibody-producing cell lines are hybridoma cell lines.
  • the cell lines can be derived from any cells which contain and are capable of expressing functionally rearranged genes which encode variable regions of the light and/or heavy chains of anti-APO-1 specificity.
  • the cell line should have the capability to assemble the chain (in the case of a single chain antibody) or chains into functional antibodies or antibody fragments.
  • lymphoid cells which naturally produce immunoglobulin are preferred.
  • Hybridoma cells which produce monoclonal anti-APO-1 antibodies can be made by the standard somatic cell
  • the animals can be immunized with purified or partially purified APO-1 or peptidic segments carrying one or more immunogenic epitopes of APO-1.
  • Such peptides can be synthesized and conjugated to a carrier protein, such as keyhole limpet hemocyanin, to be used as an immunogen.
  • the preferred animal for immunization is the mouse.
  • mice can be given about 107 APA-1-bearing cells one per weak over a four-week period by intraperitoneal
  • Antibody-producing lymphoid cells e.g. splenic
  • lymphocytes are then obtained from the immunized animal and fused with immortalizing cells (preferably a myeloma or heteromyeloma).
  • immortalizing cells preferably a myeloma or heteromyeloma.
  • myeloma cell lines are known in the art.
  • the resulting hybrid cells are clonally cultured and then screened for production of anti-APO-1 antibody.
  • Hybridomas can be screened for secretion of antibodies which induce apoptosis against a cell line which
  • APO-1 antigen expresses the APO-1 antigen.
  • An example of such a cell line is the malignant human B cell line SKW6.4.
  • Purified or partially purified APO-1 can be used to screen for hybridomas that secrete antibodies of APO-1 specificity by standard immunoadsorbant assays.
  • animal antibodies can be useful for human therapy, it may be preferable to convert animal
  • Monoclonal antibodies produced in murine or other animal systems can be converted to chimeric animal/human antibodies or to "near human" antibodies by standard techniques.
  • APO-1-binding fragments of analogues of anti-APO-1 antibodies can also be produced.
  • antibody fragments such as F(ab') 2 , Fab and F V can be produced by enzyme digestion.
  • synthetic oligopeptides representing Fab and F V analogues single chain
  • antibodies can be produced in bacterial cells by genetic engineering techniques.
  • the antibodies can be used to induce growth inhibition or apoptosis in lymphoid cells (normal or malignant) or other cells bearing APO-1.
  • anti-APO-1 antibody can be used to treat tumors bearing the APO-1 antigen.
  • growth inhibition and/or apoptosis can be induced by antibody in various types of lymphoid cell malignancies which express APO-1. These lymphoid cell malignancies include malignancies of B or T cell lymphocytes.
  • adult T cell leukemia, an HTLV-1 associated tumor can be treated with anti-APO- 1 antibody.
  • nonlymphoid tumors which bear APO-1 are candidates for the antibody therapy.
  • the anti-APO-1 antibodies are administered to a patient afflicted with the tumor in an amount that induces growth inhibition or apoptosis of APO-1 bearing cells.
  • Effective anti-tumor dosages and dosage regimens can be determined for the various types of tumors. Generally, the
  • antibodies can be given intravenously in a pharmaceutical vehicle such as saline.
  • Lymphoid tumors which express APO-1 can also be treated extracorporeally. Blood cells or blood leukocytes are removed from the patient and contacted with anti-APO-1 antibodies in amounts sufficient to reduce or eliminate tumor cells. After treatment, the blood cells or
  • leukocytes are returned to the patient.
  • the antibodies can also be used diagnostically to
  • the anti-APO-1 antibodies can be used to define subsets of normal and malignant lymphocytes based upon the
  • APO-1 expression of APO-1.
  • conventional assays for determination of cellular surface antigens can be used.
  • a sample of cells to be tested is incubated with an anti-APO-1 antibody under conditions which allow the antibody to bind APO-1 on the cell surface.
  • a second antibody directed against the anti-APO- 1 antibody is used to detect binding (e.g. if the anti- APO-1 antibody is a mouse antibody, the second antibody can be a goat anti-mouse antibody).
  • the second antibody is labelled, preferably with an enzyme or a fluorescent molecule. After incubation of the cells with the labelled antibody, the label associated with cell is detected as indication of the APO-1 expression by the cell.
  • mice were immunized once per week over a 4-week period by intraperitoneal injection of 1 x 10 7 SKW6.4 cells. Four days after the last injection, spleen cells from immunized animals were fused with the P3.X63.Ag8.653 myeloma [G. Kohler and C. Milstein, Nature 256, 495
  • MAbs monoclonal antibodies
  • Affinity and number of anti-APO-1 binding sites per cell were determined by Scatchard analysis as described [I. von Hoegen, W. Falk, G. Kojouharoff, P. H. Krammer, Eur. J. Immunol. 19, 239 (1989)]. Briefly, MAbs were iodinated by the IODO-gen method [P. J. Fraken and J. C. Speck, Biochem. Biophys. Res. Commun. 80, 849 (1980]. Aliquots of 5 x 10 6 cells were resuspended in 200 ⁇ l of culture medium containing 0.1% NaN 3 , and different concentrations of 125 I-labelled MAbs. After incubation at 4oC for 4 hours, two 95- ⁇ l portions were removed and centrifuged as described above by von Hoegen et al.
  • the T cell line CCRF-CEM.S2 was cultured in the presence of purified MAb (1 / ⁇ g/ml) in a microtiter plate for 2 hours before photography (left panel of Figure 2, control MAb 13BI; right panel, anti-APO-1).
  • the CCRF- CEM.S2 subclone was obtained by cloning cells under limiting dilution conditions from the CCRF-CEM.S2 T cell line at one cell per well in 96-well microtiter plates.
  • CCRF-CEM.S2 was selected because of its high sensitivity to programmed cell death induced by APO-1 (500 ng/ml) as measured by microscopic inspection in a 4-hour culture.
  • CCRF-CEM.S2 cells (10 per milliliter) were incubated with MAb (1 yug/ml) in culture medium at 37 C. At various times, aliquots of 10 cells were removed and DNA was prepared.
  • M marker
  • I control MAb 13BI for 2 hours ; lanes 3 to 7, anti-APO-1 for the times indicated).
  • C SKW6.4 cells were either incubated with the isotype matched control MAb FII20 ( ⁇ ), FII23 (non- binding MAb) (O), or anti-APO-1 (•) in microcultures for
  • the data represent the mean of duplicate cultures with a variation of less than 5%.
  • the cells were cultured in RPMI 1640 medium (Gibco, Grand Island, New
  • DNA fragmentation 1 x 10 8 cells were washed with cold phosphate-buffered saline and disrupted with NTE buffer, pH 8 (100 mM NaCl, 10 mM tris, 1 mM EDTA) containing 1% SDS and proteinase K (0.2 mg/ml). After incubation for 24 hours at 37oC, samples were extracted twice with phenol plus chloroform (1:1, v/v) and precipitated by ethanol. The DNA was dissolved in 38 ⁇ l of NTE buffer and digested with ribonuclease (1 mg/ml) for 30 min at 37oC.
  • IgF(ab') 2 (70 ⁇ g/ml) and analyzed by a cytofluorograph (Ortho Diagnostic Systems, Westwood, Massachusetts).
  • tritiated thymidine uptake cells (10 4 per well) were cultured in the presence of MAb (500 ng/ml) for 24 hours and labelled with [ 3 H] thymidine for 2 hours before harvest; the data in table 1 represent the mean of duplicate cultures with a variation of less than 5%.
  • Leukemic cells from patients were obtained as follows. Bone marrow cells isolated from the patients were
  • the effect of anti-APO-1 on these leukemic cells was not tested, because they died under normal culture conditions.
  • Normal human lymphocytes were obtained as follows.
  • PBMC Peripheral blood mononuclear cells
  • Ficoll Paque Pulcoll Paque (Pharmacia Inc., Uppsala, Sweden) density centrifugation.Adherent cells were removed by adherence to plastic culture vessels overnight. T cells were isolated from PBMC by rosetting with 2 amino-ethylisothyouronium-bromide (AET)-treated sheep red blood cells as described (20). Freshly prepared resting T cells (2 x 10 6 per milliliter; 96% OKTII + , 1% Tac + ) were activated with phytohemagglutinin-M (50 ⁇ g/ml)) and PMA (10 ng/ml) (Sigma Chemical Co., Kunststoff, FRG).
  • AET amino-ethylisothyouronium-bromide
  • T cells Two, 7 and 12 days later the T cells were fed with 20 to 30 U/ml or recombinant human interleukin-2 (20 to 30 U/ml).
  • T cells (5 x 10 5 per milliliter) activated for 12 days (90% OKTII + ; 60% Tac + ) were cultured in the presence of FII23 or anti-APO-1 (1 ⁇ g/ml) in triplicates for 24 hours and then labelled with [ 3 H] thymidine for a further 17 hours (see above).
  • mice Effect of anti-APO-1 on tumor growth in vivo BJAB cells (4 x 10 7 ) were injected subcutaneously into the left flank of ⁇ / ⁇ mice. After 5 weeks (day 0) the mice were injected with 500 ⁇ g of MAb into the tail vein.
  • MAb FII20 ( ⁇ ); FII23 (O); I3BI ( ⁇ ); and anti-APO-1 (•).
  • Figure 1A upper row, shows the uptake of 125 I-labelled MAb anti-APO-1 (50 ⁇ g , 50 ⁇ Ci per mouse) in the tumor at 12 hours (1), 48 hours (2), and
  • the left panel shows tumor after treatment with control MAb FII20; the right panel shows tumor after treatment with anti-APO-1.
  • Arrows indicate host vessels.
  • MAbs were radioiodinated according to the IODO-Gen method (see above). Labelled MAbs were injected into the tail vein and animals were killed by ether anesthesia at the predetermined time points. The tumors were excised and embedded in methyl- cellulose and 20- ⁇ m cryotome sections were prepared.
  • a MAb (anti-APO-1) was identified that blocks growth and induces apoptosis of SKW6.4 cells.
  • the antibody specifically immunoprecipitated an endogenously synthesized protein antigen (APO-1) from SKW6.4 cells which, under reducing conditions, was observed on SDS-polyacrylamid gel
  • anti-APO-1 specifically immunoprecipitated a minor band of 25 kD.
  • This 25-kD protein might either represent a degradation product or be noncovalently associated with the 52-kD protein.
  • Necrosis as a result, for example, of complement attack is characterized by swelling of the cells and rupture of the plasma membrane caused by an increase in permeability.
  • Cells that undergo apoptosis show a different biochemical and morphological pattern. This pattern corresponds to the one induced by anti-APO-1: condensation of the cytoplasm, membrane blebbing (Figure 2a), and endonuclease-induced DNA fragmentation (A.H. Wyllie, Nature 284, 555 (1980)) into multimers of approximately 180 bp ( Figure 2b).
  • CD22 MHC class II, IgM (immunoglobulin M), and the
  • CD22 (HD39) were kindly provided by B. Dorken (Polyclinic of the University, Heidelberg,, FRG) and monoclonal anti-
  • APO-1 was expressed on various human lymphoid B and T cell lines and was not found on a gibbon or mouse T cell line or a human monocytic cell line (Table 1). Anti-APO-1 blocked proliferation of the APO-1-positive cell lines listed in Table 1 via induction of apoptosis, and formation of a DNA ladder was observed in each case. Two hours after addition of the MAbs (1 ⁇ g/ml) the genomic DNA of each tumor line was isolated and analyzed on agarose gels as described above. Inhibition of
  • APO-1 was not restricted to cell lines in vitro but could be found on leukemic cells freshly isolated from patients (Table 1). Since APO-1 was not found on all leukemic cells anti-APO-1 may define a subpopulation of leukemias.
  • APO-1 was expressed on activated B cells (Table 1) and IgM secretion was reduced approximately fourfold by 3 days of treatment with anti-APO-1.
  • Activated B cells (10 6 per milliliter) were incubated in the presence of MAb FII23 or anti-APO-1 at 1 ug/ml. After 3 days the culture supernatants were collected and the IgM
  • IgM secretion after treatment with FII23 or anti-APO-1 was 2100 and 550 ng/ml, respectively).
  • Peripheral resting T cells did not express APO-1.
  • BJAB was the least sensitive to anti-APO-1 of the B cell panel in Table 1 and expressed only approximately 1.5 x 10 4 APO-1 epitopes per cell (4), we selected BJAB for our in vivo experiments. The reason for this choice was that only BJAB grew to large tumor masses in unirradiated ⁇ / ⁇ m mice. Five weeks after injection of BJAB cells the ⁇ / ⁇ mice carried tumors with a diameter of appoximately 1.0 to 2.5 cm ( Figure 3).
  • mice were injected intravenously with purified anti-APO-1 (500 ⁇ g per mouse) or the same quantities of various isotype-matched control antibodies (FII20, anti-MHC class I antigens, recognizing 5.8 x 10 sites per cell; or one of the two nonbinding MAbs FII23 and I3BI).
  • anti- APO-1 500 nq per mouse
  • mice carrying the APO-1-negative B cell tumor OCI.LYI with tumor diameters of 1.5, 1.8, and 3.4 cm, respectively (OCI.LYI was obtained from H. Messner, Ontario Cancer Institute, Toronto, Canada) (see also Table 1).
  • labelled MAbs were visualized by autoradiography of sections of the BJAB tumor tissue ( Figure 4a). These autoradiographs showed a pronounced binding of anti-APO-1 in the periphery but only sparse accumulation in the center of the tumor.
  • the binding control MAb FII20 showed a qualitatively similar binding pattern. There was no localization of the nonbinding control MAb FII23 above background.
  • paired label experiments D. Pressman at al., Cancer Res. 17, 845 (1957) with labelled anti-APO-1 and FII23 revealed that the specific enrichment of anti-APO-1 over FII23 in the tumor was four- and sixfold after 48 and 96 hours, respectively.
  • BJAB appeared as a solid tumor composed of densely packed large blasts with numerous mitoses, some tumor giant cells, and rare apoptotic figures (Figure 4b, left panel). The tumor was penetrated by host vessels. In contrast, almost all remaining BJAB cells of mice treated with anti-APO-1 ( Figure 4b, right panel) showed severe cytopathic changes including nuclear pycnosis and
  • apoptosis is induced by anti-APO-1 and is the mechanism of death and regression of BJAB tumor cells in vivo.
  • FII20 which strongly binds to the cell surface of BJAB tumor cells, did not cause regression of BJAB also precludes the possibility that killer cells or complement that might have bound to anti-APO-1 may have been involved in the growth inhibition and tumor
  • IL- 2 final concentration 20 U/ml
  • recombinant IL-4 final concentration of 5 ng/ml
  • C91/P1 is a cord blood T cell line
  • T cell lines used were originally derived from patients with ATL:JGCL and DCL are IL-2 dependent cell lines.
  • MJCL and MT1 are IL-2 independent cell lines which still respond to IL-2 with enhanced proliferation.
  • CRII2 and HUT102 are the
  • HTLV-I positive leukemic cell lines in which HTLV-1 was originally described. Growth of these cell lines does not depend on IL-2 in the culture medium.
  • B cell line SKW6.4 was included as a control in all experiments. Trauth B.C., Klas C., Peters A.M.J., Matzku S., Moller P., Falk W. , Debatin K-M, Drammer PH. "Monoclonal antibody-induced tumor regression by
  • Thawed leukemic cells from five patients with ATL were used for the experiments.
  • the cells from patients with a high leukemic cell count were frozen and stored in liquid nitrogen in medium containing 20% FCS and 10% DMSO. After careful thawing there was a considerable loss of cells which appears to be characteristic for ATL cells.
  • Viable cells were isolated after thawing by density gradient centrifugation (LSM, Organontechnika Corp., Durham, N.C.) and cultured in vitro for further experiments.
  • Immunofluorescence staining was determined by flow cytometry with the following antibodies: anti-Tac- antibody was used at 1 ug/10 6 cells. Anti-APO-1 (IgG3, ) and an isotype matched control non-binding antibody were used as a 10% dilution of the original hybridoma
  • Antibodies against CD3, CD4 , CD8 were purchased from Becton Dickinson (Mountain View, CA.) and used according to the manufacturer's instructions.
  • For cell surface staining 1 x 10 6 cells in 100 ⁇ l medium were incubated with the appropriate dilutions of the
  • PBS phosphate buffered saline
  • FCS phosphate buffered saline
  • Na-azide 1% FCS and 0.3% Na-azide.
  • human IgG was added to a final concentration of 100 ⁇ g/ml. After incubation for 30 m, cells were washed and incubated with a second FITC labelled goat- anti-mouse Ig antibody (TAGO Burlingame, Ca.).
  • CD4-, CD8 + , Tac + Strong expression of the APO-1 antigen was found on all cell lines. The intensity of APO-1 expression was comparable to the expression found on activated normal T cells or on APO-1 positive B and T cell lines.
  • APO-1 is also expressed on the leukemic cells from patients with ATL.
  • Thawed cells from frozen peripheral blood cells were investigated. The recovery of ATL cells after thawing is usually low. After thawing recovery ranged from 2 - 35%. These cells showed low Tac and variable APO-1 expression (3 - 15% and 1 - 53% positive cells, respectively).
  • the cells were cultured in medium supplemental with IL-2 for 5 days. Under these conditions ATL cells increased APO-1 and Tac expression. Again the intensity of APO-1 expression was comparable to the one on HTLV-1 transformed T cell lines and on other sensitive cells such as activated T cells or malignant T or B cell lines. Effect of anti-APO-1 on proliferation of ATL cells in vitro
  • APO-1 was expressed on cultured ATL cells we tested whether anti-APO-1 inhibited proliferation of these cells in vitro.
  • ATL cells were cultured either in medium alone or in medium plus IL-2 and IL-4. The reason for culturing the cells in IL-2 or IL-4 was that in some cases ATL cells showed a proliferative response to IL-2 or IL-4 without prior activation.
  • ATL cells were first cultured for five days in the presence of IL-2 (20 U/ml). During this time no net gain in cell numbers during culture was observed. The cultured cells were then incubated for 48 hours with 1 ⁇ g/ml anti-APO-1 or control antibody, respectively. Under these conditions 75 - 100% of ATL cells were dead after anti-APO-1 treatment.
  • APO-1 was also found on cultured cells from the peripheral blood of patients with ATL. Thawed cells from such patients could not directly be studied since the viability was too low after thawing. However, when cultured in vitro in medium alone or in the presence of cytokines (IL-2 or IL-4) these cells were found to express APO-1. Treatment of these cells in vitro with anti-APO-1 strongly inhibited the spontaneous IL-2 or IL-2.
  • APO-1 is a characteristic feature of HTLV-I transformed T cell lines and cultured malignant T cells from patients with ATL. Incubation of these cells and cell lines with the anti-APO-1 antibody induces apoptosis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

On décrit un antigène 52kD associé à l'apoptose cellulaire. L'antigène est exprimé par des cellules lymphoïdes activées et malignes. Les anticorps qui se fixent sur les antigènes provoquent l'inhibition de la croissance cellulaire et l'apoptose.
PCT/EP1990/000111 1990-01-19 1990-01-19 Antigene de surface cellulaire associe a l'apoptose cellulaire WO1991010448A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2502015A JP2963535B2 (ja) 1990-01-19 1990-01-19 Ｈｔｌｖ−１ウイルス感染細胞の増殖阻害用組成物
CA002071205A CA2071205C (fr) 1990-01-19 1990-01-19 Antigene de la surface cellulaire associe a l'apoptose cellulaire
PCT/EP1990/000111 WO1991010448A1 (fr) 1990-01-19 1990-01-19 Antigene de surface cellulaire associe a l'apoptose cellulaire
EP90901787A EP0511202B1 (fr) 1990-01-19 1990-01-19 Antigene de surface cellulaire associe a l'apoptose cellulaire
DE69009497T DE69009497T2 (de) 1990-01-19 1990-01-19 Mit zellularer apoptosis assoziiertes zelloberflächenantigen.
AT90901787T ATE106248T1 (de) 1990-01-19 1990-01-19 Mit zellularer apoptosis assoziiertes zelloberflächenantigen.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002071205A CA2071205C (fr) 1990-01-19 1990-01-19 Antigene de la surface cellulaire associe a l'apoptose cellulaire
PCT/EP1990/000111 WO1991010448A1 (fr) 1990-01-19 1990-01-19 Antigene de surface cellulaire associe a l'apoptose cellulaire

Publications (1)

Publication Number Publication Date
WO1991010448A1 true WO1991010448A1 (fr) 1991-07-25

Family

ID=25675217

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1990/000111 WO1991010448A1 (fr) 1990-01-19 1990-01-19 Antigene de surface cellulaire associe a l'apoptose cellulaire

Country Status (1)

Country Link
WO (1) WO1991010448A1 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0510691A1 (fr) * 1991-04-26 1992-10-28 Osaka Bioscience Institute ADN codant un antigène de surface cellulaire humaine
WO1995018819A1 (fr) * 1994-01-07 1995-07-13 Immunex Corporation Ligand fixant l'antigene fas
EP0709097A1 (fr) * 1994-09-27 1996-05-01 Santen Pharmaceutical Co., Ltd. Anticorps anti-Fas contre les maladies rheumatiques
EP0716095A1 (fr) * 1994-12-08 1996-06-12 Oriental Yeast Co., Ltd. Procédé de détermination quantitative de l'antigène fas
WO1996040041A2 (fr) * 1995-06-07 1996-12-19 Chiron Corporation ANTICORPS DE L'ANTIGENE Fas CAPABLES D'INHIBER L'APOPTOSE
US5620889A (en) * 1993-10-14 1997-04-15 Immunex Corporation Human anti-Fas IgG1 monoclonal antibodies
WO1997029130A1 (fr) * 1996-02-08 1997-08-14 Louise Desjardins Anticorps agissant contre la gp46 et fragments de ceux-ci, et leur utilisation
US5830469A (en) * 1993-10-14 1998-11-03 Immunex Corporation Fas antagonists and uses thereof
US6348334B1 (en) 1993-11-10 2002-02-19 Mochida Pharmaceutical Co., Ltd. DNA encoding Fas ligand
US6746673B2 (en) 1999-05-24 2004-06-08 Sankyo Company, Limited Pharmaceutical compositions containing anti-Fas antibody
US6897295B1 (en) 1993-11-10 2005-05-24 Mochida Pharmaceutical Co., Ltd. Antibodies and fragments thereof to Fas ligand and Fas ligand derived polypeptides
US7705195B2 (en) 2002-06-07 2010-04-27 Genentech, Inc. Screening method
WO2014037785A2 (fr) 2012-09-06 2014-03-13 Institute Of Cell Biology, National Academy Of Sciences Of Ukraine Anticorps catalytiques et leurs utilisations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0311438A2 (fr) * 1987-10-08 1989-04-12 Ronald James Billing Antigène capable de se lier à des cellules tumorales

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0311438A2 (fr) * 1987-10-08 1989-04-12 Ronald James Billing Antigène capable de se lier à des cellules tumorales

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Dialog Informational Service, File 154: Medline 83-90/Oct, accession no. 05102476, Medline accession no. 84026476, Acuto O. et al: "The human *T* cell *receptor*: appearance in ontogeny and bio-chemical relationship of alpha and beta subunits on IL-2 dependent clones and T cell tumors", & Cell Oct 1983, 34 (3) p717-26 *
Dialog Informational Service, File 154: Medline 83-90/Oct, accession no. 07153202, Medline accession no. 90060202, Takahashi S. et al: "DNA fragmentation and cell death mediated by T cell antigen receptor/CD3 complex on a leukemia T cell line", & Eur J Immunol (GERMANY, WEST) Oct 1989, 19 (10) p1911-9 *
Dialog Informational Service, File 154: Medline 83-90/Oct, accesssion no. 06218500, Medline accession no. 87192500, Schwarting R. et al: "Immunoprecipitation of the interleukin-2 receptor from Hodgkin's disease derived cell lines by *monoclonal* antibodies", & Hematol Oncol Jan-Mar 1987, 5 (1) p57-64 *
NATURE, Vol. 337, January 1989 C.A. Smith et al.: "Antibodies to CD3/T-cell receptor complex induce death by apoptosis in immature T cells in thymic cultures ", *
SCIENCE, Vol. 245, July 1989 B.C. Trauth et al.: "Monoclonal Antibody-Mediated Tumor Regression by Induction of Apoptosis ", *
SCIENCE, Vol. 248, June 1990 M. Blackman et al.: "The Role of the T Cell Receptor in Positive and Negative Selection of Developing T Cells ", *

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0510691A1 (fr) * 1991-04-26 1992-10-28 Osaka Bioscience Institute ADN codant un antigène de surface cellulaire humaine
US5874546A (en) * 1991-04-26 1999-02-23 Osaka Bioscience Institute Fas antigen
US5620889A (en) * 1993-10-14 1997-04-15 Immunex Corporation Human anti-Fas IgG1 monoclonal antibodies
US6015559A (en) * 1993-10-14 2000-01-18 Immunex Corporation Fas antagonists
US5830469A (en) * 1993-10-14 1998-11-03 Immunex Corporation Fas antagonists and uses thereof
US6348334B1 (en) 1993-11-10 2002-02-19 Mochida Pharmaceutical Co., Ltd. DNA encoding Fas ligand
US6897295B1 (en) 1993-11-10 2005-05-24 Mochida Pharmaceutical Co., Ltd. Antibodies and fragments thereof to Fas ligand and Fas ligand derived polypeptides
US7622554B2 (en) 1993-11-10 2009-11-24 Mochida Pharmaceutical Co., Ltd. FAS ligand derived polypeptides
WO1995018819A1 (fr) * 1994-01-07 1995-07-13 Immunex Corporation Ligand fixant l'antigene fas
EP0709097A1 (fr) * 1994-09-27 1996-05-01 Santen Pharmaceutical Co., Ltd. Anticorps anti-Fas contre les maladies rheumatiques
US6086877A (en) * 1994-09-27 2000-07-11 Santen Pharmaceutical Co., Ltd. Therapeutic agent for rheumatic disease
EP0716095A1 (fr) * 1994-12-08 1996-06-12 Oriental Yeast Co., Ltd. Procédé de détermination quantitative de l'antigène fas
WO1996040041A3 (fr) * 1995-06-07 1997-03-13 Chiron Corp ANTICORPS DE L'ANTIGENE Fas CAPABLES D'INHIBER L'APOPTOSE
WO1996040041A2 (fr) * 1995-06-07 1996-12-19 Chiron Corporation ANTICORPS DE L'ANTIGENE Fas CAPABLES D'INHIBER L'APOPTOSE
WO1997029130A1 (fr) * 1996-02-08 1997-08-14 Louise Desjardins Anticorps agissant contre la gp46 et fragments de ceux-ci, et leur utilisation
US6746673B2 (en) 1999-05-24 2004-06-08 Sankyo Company, Limited Pharmaceutical compositions containing anti-Fas antibody
US7705195B2 (en) 2002-06-07 2010-04-27 Genentech, Inc. Screening method
WO2014037785A2 (fr) 2012-09-06 2014-03-13 Institute Of Cell Biology, National Academy Of Sciences Of Ukraine Anticorps catalytiques et leurs utilisations

Similar Documents

Publication Publication Date Title
Trauth et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis
Tanaka et al. A novel monoclonal antibody against murine IL-2 receptor beta-chain. Characterization of receptor expression in normal lymphoid cells and EL-4 cells.
Carrel et al. Subsets of human Ia-like molecules defined by monoclonal antibodies
Brenner et al. Two forms of the T-cell receptor γ protein found on peripheral blood cytotoxic T lymphocytes
Clark et al. Polypeptides on human B lymphocytes associated with cell activation
Sanchez-Madrid et al. Antigens involved in mouse cytolytic T-lymphocyte (CTL)-mediated killing: functional screening and topographic relationship
EP0117114A2 (fr) Anticorps monoclonal
IL108501A (en) Antibodies and pharmaceutical compositions containing them
WO1991010448A1 (fr) Antigene de surface cellulaire associe a l'apoptose cellulaire
Haregewoin et al. Cellular expression of a GPI-linked T cell activation protein
EP0203403B1 (fr) Cellule T clonée capable de reconnaître des tumeurs et un récepteur antigénique de cellule T
Vuist et al. Potentiation by interleukin 2 of Burkitt's lymphoma therapy with anti-pan B (anti-CD19) monoclonal antibodies in a mouse xenotransplantation model
CA2128151A1 (fr) Recepteurs de l'interleukine 12 et anticorps
US5891434A (en) Monoclonal antibodies to the APO-1 antigen
US20230365686A1 (en) Humanized antibody specific for cd22 and chimeric antigen receptor using the same
EP0511202B1 (fr) Antigene de surface cellulaire associe a l'apoptose cellulaire
CA2070182C (fr) Immunoglobuline chimerique pour recepteurs cda
Meffre et al. Cell surface expression of surrogate light chain (ΨL) in the absence of μ on human pro‐B cell lines and normal pro‐B cells
CA2071205C (fr) Antigene de la surface cellulaire associe a l'apoptose cellulaire
Freedman et al. Novel immunologic strategies in ovarian carcinoma
Rankin et al. Mouse monoclonal antibodies against the idiotype of human B cell non‐Hodgkin lymphomas: production, characterization and use to monitor the progress of disease
Haars et al. Modulation of T-cell antigen receptor on lymphocyte membrane
AU738749B2 (en) Targeted cytotoxic cells
van Endert et al. Monoclonal antibodies to idiotype inhibit in vitro growth of human B-cell lymphomas
Baumal et al. Induction of cytotoxic factors by immunization of mice with Freund's adjuvant components

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 2071205

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1990901787

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1990901787

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1990901787

Country of ref document: EP